Book a Meeting

ADCC-Enhanced Anti-Human TIGIT (Tiragolumab) Antibody (CAT#: BioBet-CB-093LX) Datasheet

Target
TIGIT
Isotype
IgG1
Description
ADCC-Enhanced Anti-Human TIGIT (Tiragolumab) Antibody is a glycosylation-modified anti- therapeutic antibody.
Indication
Chronic lymphocytic leukemia; follicular lymphoma; some types of non-Hodgkin lymphoma (NHL);some non-cancer related illnesses
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced TIGIT antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
TIGIT
Full Name
T cell immunoreceptor with Ig and ITIM domains
Background
This gene encodes a member of the PVR (poliovirus receptor) family of immunoglobin proteins. The product of this gene is expressed on several classes of T cells including follicular B helper T cells (TFH). The protein has been shown to bind PVR with high affinity; this binding is thought to assist interactions between TFH and dendritic cells to regulate T cell dependent B cell responses.[provided by RefSeq, Sep 2009]
Alternative Names
T cell immunoreceptor with Ig and ITIM domains; VSIG9; VSTM3; WUCAM; TIGIT
Gene ID
201633
UniProt ID
Q495A1
Field of research
Cell Biology, Immunology,
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
Tiragolumab
Host
Human
Species Reactivity
Human
Description
ADCC-Enhanced Anti-Human TIGIT (Tiragolumab) Antibody is derived from clone Tiragolumab, which is a Human monoclonal antibody with enhanced ADCC activity. Antibody-dependent cellular cytotoxicity (ADCC) is an important function of antibody. It is a part of the humoral immune response to limit and contain infection. The antibody targets the TIGIT, and it is intended for the research of Small cell lung cancer .
Indication
Small cell lung cancer

Related Products

BetterBet™ Anti-TIGIT Half-Life Extended Antibody (CAT#: AES-0622-ZP1099)
BetterBet™ Anti-TIGIT On-Target Antibody (CAT#: AES-0622-ZP771)
BetterBet™ Anti-TIGIT FcγRIIB Binding Enhanced Antibody (CAT#: AES-0622-ZP443)
Non-Fucosylated Anti-Human TIGIT (14D7) Therapeutic Antibody (CAT#: BioBet-1730ZP)
Non-Fucosylated Anti-Human TIGIT (26B10) Therapeutic Antibody (CAT#: BioBet-1731ZP)
BetterBet™ Anti-TIGIT Recycling Antibody (CAT#: AES-0622-ZP115)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.